Accessibility Menu
BioCardia logo

BioCardia(NASDAQ) BCDA

Current Price$0.85
Market Cap$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-98%
1 Year-63%
1 Month-20%
BioCardia last closing stock price
MetricPriceDate
Last closeUSD 0.852026-07-24
BioCardia stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.94%USD 0.832026-07-17
1 month-19.8%USD 1.062026-06-24
3 month-26.72%USD 1.162026-04-24
Year to date-31.99%USD 1.252025-12-31
1 year-63.2%USD 2.312025-07-24
3 year-94.58%USD 15.682023-07-25
5 year-98.47%USD 55.652021-07-23
Since inception-99.56%USD 204.122016-10-26

BioCardia Financials at a Glance

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.78M

EPS (TTM)

-$1.03

P/E Ratio

-0.82

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Price

$0.85

Volume

129,816.895

Open

$0.90

Previous Close

$0.85

Daily Range

$0.85 - $0.91

52-Week Range

$0.78 - $2.38

Estimated Earnings Date

Aug 10, 2026

BCDA News

Foolcom-Featured.png

BioCardia Narrows Loss in Fiscal Q2

Motley Fool Markets TeamAug 11, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioCardia

BioCardia develops therapies for heart and lung diseases using patients’ own or donor cells. Its main products help doctors treat heart failure and deliver medicine directly to the heart. These solutions aim to improve care for people with serious heart conditions.

Products and Services

  • CardiAMP Cell Therapy: Uses a patient’s own cells to treat heart failure and poor blood flow to the heart. (0% of 2025 revenue)
  • CardiALLO Allogeneic Therapy: Uses donor cells for heart failure and lung injury treatment. (0% of 2025 revenue)
  • Helix Delivery System: Catheter device that delivers therapies directly into heart muscle. (0% of 2025 revenue)
  • Morph Guides and Sheaths: Steerable tubes for vascular access in medical procedures. (0% of 2025 revenue)
  • Partnering Agreements: Supports other companies’ clinical trials with delivery systems and technical help. (0% of 2025 revenue)

Growth and Expansion

  • Launched pivotal clinical trials for CardiAMP and CardiALLO therapies in the U.S. and Japan (2024-2025).
  • Entered new partnerships to supply delivery systems for external clinical trials (2025).
  • Advanced regulatory preparations for CardiAMP and Helix systems in the U.S. and Japan, including FDA Q-Submissions and PMDA clinical consultations (2025–early 2026).
  • Raised new capital through multiple equity offerings in 2025 to fund operations.

What Makes BioCardia Stand Out

BioCardia’s therapies use both patient and donor cells, offering personalized and “off-the-shelf” options. Its Helix system allows precise, minimally invasive delivery of treatments to the heart. The company holds over 70 patents and received special FDA review status for its lead therapy.

Five Things You Need to Know

  • Revenue was $0 in 2025, down 100% from 2024 and 2023.
  • Operating loss was $8.3 million in 2025, up 3.8% from 2024.
  • Cash used in operations was $7.4 million in 2025, improving 5.7% from 2024.
  • Raised $7.6 million in 2025 through equity offerings and at-the-market sales.

Bottom Line

BioCardia focuses on cell-based therapies and delivery systems for heart and lung diseases. The company remains in clinical development, with ongoing funding needs and no product revenue as of 2025.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

Peter Alan Altman, PhD

Website

www.biocardia.com

Headquarters

Sunnyvale, CA 94085, US

BCDA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5456.14%

Return on Capital

-581.73%

Return on Assets

-454.15%

Earnings Yield

-1.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.88M

Volume

129.82K

Avg. Volume

3.14M

Financials (TTM)

Gross Profit

-$1.78M

Operating Income

-$7.82M

EBITDA

-$7.35M

Operating Cash Flow

-$7.48M

Capital Expenditure

-$10.00K

Free Cash Flow

-$7.49M

Cash & ST Invst.

$951.00K

Total Debt

$412.00K

BioCardia Performance Analysis

BioCardia annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,352,00033.2%
20232023-12-31USD 477,000-64.7%
20242024-12-31USD 58,000-87.8%
20252025-12-31USD 0N/A
BioCardia sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
BioCardia annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.08-9.9%
20232023-12-31USD -8.19-18.7%
20242024-12-31USD -2.90-64.7%
20252025-12-31USD -1.23-57.4%
BioCardia sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3059.6%
Q32025-09-3040.0%
Q42025-12-3125.0%
Q12026-03-31-16.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$124.00K

+91.9%

Gross Margin

0.00%

N/A

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$744.30K

N/A

Employees

17

N/A

Net Income

-$2.26M

+16.7%

EBITDA

-$2.14M

+20.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$951.00K

+0.2%

Total Debt

$412.00K

-51.5%

Accounts Receivable

$20.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$412.00K

+3.5%

Return on Assets

-4.54%

N/A

Return on Invested Capital

7.33%

N/A

Free Cash Flow

-$1.66M

-2.7%

Operating Cash Flow

-$1.66M

-2.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHIOPhio Pharmaceuticals Corp.
$1.04-2.80%
INABIN8bio, Inc.
$1.20+0.84%
KPRXKiora Pharmaceuticals, Inc.
$2.55+2.00%
APVOAptevo Therapeutics Inc.
$4.39+0.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About BCDA

What is the current price of BioCardia?

BioCardia is trading at $0.85 per share.

What is the 52-week range for BioCardia?

Over the past 52 weeks, BioCardia has traded between $0.78 and $2.38.

How much debt does BioCardia have?

As of the most recent reporting period, BioCardia reported total debt of $412.00K.

How much cash does BioCardia have on hand?

BioCardia reported $951.00K in cash and cash equivalents in its most recent financial results.

What is BioCardia’s dividend yield?

BioCardia does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services